National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

作者：Madan Jagasia, Hildegard Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff, Edward W. Cowen, Jeanne Palmer, Daniel J. Weisdorf, Nathaniel S. Treister, Guang‐Shing Cheng, Holly Kerr, Pamela Stratton, Rafael F. Duarte, George B. McDonald, Yoshihiro Inamoto, Afonso Celso Vigorito, Sally Arai, Manuel B. Datiles, David A. Jacobsohn, Theo Heller, Carrie L. Kitko, Sandra A. Mitchell, Paul J. Martin, Howard M. Shulman, Roy S. Wu, Corey Cutler, Georgia B. Vogelsang, Stephanie J. Lee, Steven Z. Pavletic, Mary E.D. Flowers · 发表于：Transplantation and Cellular Therapy · 年份：2014 · DOI：10.1016/j.bbmt.2014.12.001 · 被引用次数：5476 · 研究领域：Hematopoietic Stem Cell Transplantation、Mesenchymal stem cell research、Corneal Surgery and Treatments

The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.